Brokerages Set Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) PT at $6.10

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) has been given a consensus rating of “Moderate Buy” by the six research firms that are currently covering the company, Marketbeat reports. One research analyst has rated the stock with a hold rating and five have given a buy rating to the company. The average 1 year price target among brokers that have updated their coverage on the stock in the last year is $6.25.

A number of brokerages recently commented on XERS. Craig Hallum increased their price target on Xeris Biopharma from $5.00 to $6.50 and gave the company a “buy” rating in a research report on Friday, March 7th. Jefferies Financial Group reaffirmed a “buy” rating and set a $6.00 price target (up from $4.00) on shares of Xeris Biopharma in a research report on Wednesday, January 29th. Leerink Partners increased their price target on Xeris Biopharma from $5.00 to $6.00 and gave the company an “outperform” rating in a research report on Friday, March 7th. Piper Sandler reaffirmed a “neutral” rating and set a $4.00 price target (up from $3.00) on shares of Xeris Biopharma in a research report on Friday, March 7th. Finally, Oppenheimer raised their target price on Xeris Biopharma from $6.00 to $7.00 and gave the stock an “outperform” rating in a research report on Friday, May 9th.

Xeris Biopharma Trading Up 3.2%

Shares of XERS opened at $4.79 on Friday. The company has a market capitalization of $749.08 million, a price-to-earnings ratio of -10.64 and a beta of 1.10. The stock has a 50 day moving average of $4.71 and a 200 day moving average of $3.89. Xeris Biopharma has a 12 month low of $1.86 and a 12 month high of $6.07.

Xeris Biopharma (NASDAQ:XERS) last issued its quarterly earnings results on Thursday, May 8th. The company reported ($0.06) EPS for the quarter, beating analysts’ consensus estimates of ($0.07) by $0.01. The business had revenue of $57.80 million for the quarter, compared to analysts’ expectations of $57.61 million. As a group, equities research analysts predict that Xeris Biopharma will post -0.41 earnings per share for the current year.

Insiders Place Their Bets

In other news, insider Beth Hecht sold 40,000 shares of Xeris Biopharma stock in a transaction on Thursday, March 20th. The stock was sold at an average price of $5.43, for a total value of $217,200.00. Following the completion of the transaction, the insider now directly owns 1,353,510 shares in the company, valued at approximately $7,349,559.30. The trade was a 2.87% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 6.47% of the company’s stock.

Hedge Funds Weigh In On Xeris Biopharma

Hedge funds have recently made changes to their positions in the stock. NewEdge Advisors LLC purchased a new position in shares of Xeris Biopharma in the fourth quarter valued at $34,000. Apella Capital LLC purchased a new position in shares of Xeris Biopharma in the first quarter valued at $55,000. Xponance Inc. purchased a new position in shares of Xeris Biopharma in the first quarter valued at $57,000. FORA Capital LLC purchased a new position in shares of Xeris Biopharma in the first quarter valued at $60,000. Finally, FNY Investment Advisers LLC purchased a new position in shares of Xeris Biopharma in the first quarter valued at $63,000. 42.75% of the stock is currently owned by hedge funds and other institutional investors.

About Xeris Biopharma

Xeris Biopharma Holdings, Inc, a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.